In many cases of malignant melanoma, the effect of targeted treatment is lost over time. A research team has now discovered that a factor secreted by tumor cells is responsible for the resistance. These findings could pave the way for more effective therapies.
Quelle: ScienceDaily | Immunsystem
Titelbild/Grafik: ScienceDaily News
Kommentare und Fragen
Möchten Sie zu diesem Inhalt ein Kommentar abgeben oder haben Sie dazu eine Frage, dann machen Sie dies bitte immer auf der Herausgeberseite!
Weiteres von ScienceDaily | Allergy
- CAR-T cell therapy for cancer causes 'brain fog,' study shows
- Fat-rich fluid fuels immune failure in ovarian cancer
- Researchers map 7,000-year-old genetic mutation that protects against HIV
- Mammal's lifespans linked to brain size and immune system function, says new study
- Reactivity to tumor antigens is important for TIL therapy
- Enhanced CAR T cell therapy offers new strategy for lymphoma
- Vaccines of the future: Harnessing the immune system for long-lasting protection
- Insights on preventing organ transplant rejection
- Dual-action approach targeting inflammation shows potential as Type 1 diabetes treatment
- Discovery of antibiotic resistance in newly identified bacterium
